Article

Genentech changes support programs for ranibizumab access

South San Francisco, CA-Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis), including Lucentis Access Solutions and the Genentech Access to Care Foundation, in an effort to improve enrollment timing and broaden eligibility requirements.

South San Francisco, CA-Genentech has changed its provider and patient support programs related to ranibizumab (Lucentis), including Lucentis Access Solutions and the Genentech Access to Care Foundation, in an effort to improve enrollment timing and broaden eligibility requirements.

The changes include:

  • Confirmation by phone-within 48 hours in most cases-that a patient who is uninsured or denied coverage is or may be eligible for free medication.

  • Conditional enrollment, via a letter faxed to the physician’s office, for eligible patients with inconclusive insurance coverage who otherwise qualify medically and financially.

  • Increased support to independent, non-profit, co-pay organizations, with a particular focus on groups that the company has determined have fast and efficient processes in place, such as the Chronic Disease Fund.

  • Expanded eligibility criteria for all of the company’s product access programs, including an increased annual adjusted gross income level (now $100,000, formerly $75,000) for patients who meet approved medical criteria as well as for patients who have reached their maximum lifetime insurance limits.

For more information, physicians and patients may contact 866/724-9394 or www.lucentisaccesssolutions.com.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.